Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlotte de Jonge

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|June 26, 2012
[Practice guideline for the treatment of morbid obesity]Froukje J Verdam, Charlotte de Jonge, Jan Willem M Greve
Obesity Surgery|January 11, 2019
Effect of the EndoBarrier Device: a 4-Year Follow-up of a Multicenter Randomized Clinical TrialSelwyn van Rijn, Yvonne G M Roebroek, Charlotte de Jonge, et al.
Annals of Surgery|July 30, 2014
The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trialParviez Koehestanie, Charlotte de Jonge, Frits J Berends, et al.
Obesity Surgery|December 21, 2013
Six months of treatment with the endoscopic duodenal-jejunal bypass liner does not lead to decreased systemic inflammation in obese patients with type 2 diabetesCharlotte de Jonge, Sander S Rensen, Hedwig M A D'Agnolo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 8, 2013
Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver diseaseCharlotte de Jonge, Sander S Rensen, Ger H Koek, et al.
Obesity (Silver Spring, Md.)|March 26, 2013
Human intestinal microbiota composition is associated with local and systemic inflammation in obesityFroukje J Verdam, Susana Fuentes, Charlotte de Jonge, et al.
Obesity Surgery|November 8, 2017
The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort StudySelwyn van Rijn, Bark Betzel, Charlotte de Jonge, et al.
Plos One|October 10, 2014
Complement alternative pathway activation in human nonalcoholic steatohepatitisFilip M Segers, Froukje J Verdam, Charlotte de Jonge, et al.
Obesity Surgery|October 9, 2015
Impact of Duodenal-Jejunal Exclusion on Satiety HormonesCharlotte de Jonge, Sander S Rensen, Froukje J Verdam, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 15, 2013
PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinomaRachel L G M Blom, Inge R Steenbakkers, Guido Lammering, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Nederlands Tijdschrift Voor Geneeskunde|June 26, 2012
[Practice guideline for the treatment of morbid obesity]Froukje J Verdam, Charlotte de Jonge, Jan Willem M Greve
Obesity Surgery|January 11, 2019
Effect of the EndoBarrier Device: a 4-Year Follow-up of a Multicenter Randomized Clinical TrialSelwyn van Rijn, Yvonne G M Roebroek, Charlotte de Jonge, et al.
Annals of Surgery|July 30, 2014
The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trialParviez Koehestanie, Charlotte de Jonge, Frits J Berends, et al.
Obesity Surgery|December 21, 2013
Six months of treatment with the endoscopic duodenal-jejunal bypass liner does not lead to decreased systemic inflammation in obese patients with type 2 diabetesCharlotte de Jonge, Sander S Rensen, Hedwig M A D'Agnolo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 8, 2013
Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver diseaseCharlotte de Jonge, Sander S Rensen, Ger H Koek, et al.
Obesity (Silver Spring, Md.)|March 26, 2013
Human intestinal microbiota composition is associated with local and systemic inflammation in obesityFroukje J Verdam, Susana Fuentes, Charlotte de Jonge, et al.
Obesity Surgery|November 8, 2017
The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort StudySelwyn van Rijn, Bark Betzel, Charlotte de Jonge, et al.
Plos One|October 10, 2014
Complement alternative pathway activation in human nonalcoholic steatohepatitisFilip M Segers, Froukje J Verdam, Charlotte de Jonge, et al.
Obesity Surgery|October 9, 2015
Impact of Duodenal-Jejunal Exclusion on Satiety HormonesCharlotte de Jonge, Sander S Rensen, Froukje J Verdam, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 15, 2013
PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinomaRachel L G M Blom, Inge R Steenbakkers, Guido Lammering, et al.
Pageof 2